Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference
Stocks in this Quantisnow insightHealth Care
Historical context for ASND
Across the 8 sessions after earlier ASND headlines, the stock closed higher 5 times and lower 3 times, with a median move of 1.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ASND | SPY |
|---|---|---|---|
| Jan 9, 2026 | Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH) | -2.8% | +0.7% |
| Jan 5, 2026 | Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference | -0.1% | +0.7% |
| Nov 26, 2025 | Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia | +1.6% | +0.7% |
| Nov 18, 2025 | Wolfe Research initiated coverage on Ascendis Pharma with a new price targetand 1 other headline that session | +0.3% | -0.8% |
| Nov 13, 2025 | Ascendis Pharma Reports Third Quarter 2025 Financial Results | +3.6% | -1.7% |
| Nov 7, 2025 | New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism | -0.8% | +0.1% |
Keep researching ASND
Quantisnow market dataNASDAQ
ASND
Ascendis Pharma A/S
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2015
Get push alerts for ASND
Full ASND profile on Quantisnow Follow ASND and get a push notification the moment its next story breaks.